Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation will highlight findings on tissue concentration–driven effects and organ-specific outcomes beyond traditional plasma pharmacokinetics.
The research underscores the importance of tissue-level drug distribution in determining toxicity profiles, which represents a significant advancement in understanding how drugs interact with biological systems. This approach moves beyond conventional plasma measurements to examine how drugs accumulate in specific organs and tissues, providing more comprehensive safety assessments.
The data supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations. These advanced delivery methods could potentially enhance therapeutic effectiveness while minimizing adverse effects by controlling how drugs distribute throughout the body. The findings have particular relevance for oncology treatments where precise drug targeting is crucial for patient outcomes.
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics. The company maintains a primary focus in oncology, where improved drug delivery systems could significantly impact treatment success rates.
Oncotelic Therapeutics is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with special emphasis on rare pediatric cancers. The company has rare pediatric designation for Diffuse Intrinsic Pontine Glioma through OT-101 via its joint venture GMP Bio, as well as designations for melanoma and Acute Myeloid Leukemia through other compounds.
The latest news and updates relating to Oncotelic Therapeutics are available in the company’s newsroom at https://ibn.fm/OTLC. BioMedWire, which distributed the announcement, is a specialized communications platform focusing on developments in biotechnology, biomedical sciences, and life sciences sectors. More information about BioMedWire is available at https://www.BioMedWire.com, with full terms of use and disclaimers accessible at https://www.BioMedWire.com/Disclaimer.
The presentation at the Society of Toxicology meeting represents an important step in advancing understanding of drug toxicity mechanisms and developing more effective delivery systems for cancer therapeutics. As research continues to evolve, tissue-level analysis of drug distribution may become increasingly important in drug development and regulatory approval processes.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oncotelic Subsidiary Sapu Nano to Present Everolimus Toxicology Data at Society of Toxicology 2026 Meeting.